The Global Drug Gap Export

@article{citeulike:3145868, abstract = {Global inequities in access to pharmaceutical products exist between rich and poor countries because of market and government failures as well as huge income differences. Multiple policies are required to address this global drug gap for three categories of pharmaceutical products: essential drugs, new drugs, and yet-to-be-developed drugs. Policies should combine "push" approaches of financial subsidies to support targeted drug development, "pull" approaches of financial incentives such as market guarantees, and "process" approaches aimed at improved institutional capacity. Constructive solutions are needed that can both protect the incentives for research and development and reduce the inequities of access.}, author = {Reich, Michael R.}, citeulike-article-id = {3145868}, citeulike-linkout-0 = {http://dx.doi.org/10.2307/3074885}, citeulike-linkout-1 = {http://www.jstor.org/stable/3074885}, doi = {10.2307/3074885}, issn = {00368075}, journal = {Science}, keywords = {development, patents}, number = {5460}, pages = {1979--1981}, posted-at = {2008-08-21 20:54:07}, priority = {2}, publisher = {American Association for the Advancement of Science}, series = {New Series}, title = {The Global Drug Gap}, url = {http://dx.doi.org/10.2307/3074885}, volume = {287}, year = {2000} }

TY - JOUR ID - citeulike:3145868 L3 - citeulike-article-id:3145868 N2 - Global inequities in access to pharmaceutical products exist between rich and poor countries because of market and government failures as well as huge income differences. Multiple policies are required to address this global drug gap for three categories of pharmaceutical products: essential drugs, new drugs, and yet-to-be-developed drugs. Policies should combine "push" approaches of financial subsidies to support targeted drug development, "pull" approaches of financial incentives such as market guarantees, and "process" approaches aimed at improved institutional capacity. Constructive solutions are needed that can both protect the incentives for research and development and reduce the inequities of access. IS - 5460 JF - Science SE - New Series SN - 00368075 EP - 1981 TI - The Global Drug Gap PB - American Association for the Advancement of Science VL - 287 SP - 1979 KW - development KW - patents AU - Reich, Michael PY - 2000/// UR - http://dx.doi.org/10.2307/3074885 ER -